Seres Therapeutics, Inc. 8-K Filing

Ticker: MCRB · Form: 8-K · Filed: Jan 13, 2025 · CIK: 1609809

Seres Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanySeres Therapeutics, Inc. (MCRB)
Form Type8-K
Filed DateJan 13, 2025
Pages2
Reading Time2 min
Key Dollar Amounts$0.001
Sentimentneutral

Sentiment: neutral

FAQ

What type of filing is this?

This is a 8-K filing submitted by Seres Therapeutics, Inc. (ticker: MCRB) to the SEC on Jan 13, 2025.

What are the key financial figures in this filing?

Key dollar amounts include: $0.001 (ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar).

How long is this filing?

Seres Therapeutics, Inc.'s 8-K filing is 2 pages with approximately 570 words. Estimated reading time is 2 minutes.

Where can I view the full 8-K filing?

The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.

Filing Stats: 570 words · 2 min read · ~2 pages · Grade level 10.1 · Accepted 2025-01-13 08:06:36

Key Financial Figures

  • $0.001 — ich registered Common stock, par value $0.001 per share MCRB The Nasdaq Stock Mar

Filing Documents

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits. The following Exhibit 99.1 relates to Item 7.01 and shall be deemed to be furnished, and not filed: Exhibit No. Description 99.1 Seres Therapeutics, Inc. Corporate Presentation as of January 2025 104 Cover Page Interactive Data File - the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: January 13, 2025 SERES THERAPEUTICS, INC. By: /s/ Thomas J. DesRosier Name: Thomas J. DesRosier Title: Chief Legal Officer and Executive Vice President

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.